Quarterly Report — Form 10-Q
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.05M
2: EX-10.1 Material Contract HTML 107K
3: EX-10.2 Material Contract HTML 89K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
14: R1 Document and Entity Information HTML 77K
15: R2 Condensed Consolidated Balance Sheets HTML 112K
16: R3 Condensed Consolidated Balance Sheets HTML 46K
(Parenthetical)
17: R4 Condensed Consolidated Statements of Operations HTML 114K
and Comprehensive Loss
18: R5 Condensed Consolidated Statements of Stockholders' HTML 91K
Equity
19: R6 Condensed Consolidated Statements of Cash Flows HTML 132K
20: R7 Basis of Presentation HTML 44K
21: R8 License and Distribution Agreements HTML 33K
22: R9 Summary of Significant Accounting Policies HTML 37K
23: R10 Investment in Equity Securities, at fair value and HTML 64K
long-term investments
24: R11 Inventories HTML 36K
25: R12 Leases HTML 62K
26: R13 Intangible Assets HTML 50K
27: R14 Assets Held for Sale HTML 39K
28: R15 Grants HTML 26K
29: R16 Note Payable HTML 38K
30: R17 Redeemable Noncontrolling Interest HTML 54K
31: R18 Stockholders' Equity HTML 42K
32: R19 Net Loss Per Share HTML 60K
33: R20 Stock-Based Compensation HTML 74K
34: R21 Income Taxes HTML 28K
35: R22 Fair Value Measurements HTML 77K
36: R23 Related Party Transactions HTML 29K
37: R24 Acrotech License Arrangements HTML 30K
38: R25 Commitments HTML 29K
39: R26 Subsequent Event HTML 29K
40: R27 Summary of Significant Accounting Policies HTML 50K
(Policies)
41: R28 Investment in Equity Securities, at fair value and HTML 55K
long-term investments (Tables)
42: R29 Inventories (Tables) HTML 36K
43: R30 Leases (Tables) HTML 62K
44: R31 Intangible Assets (Tables) HTML 49K
45: R32 Assets Held for Sale (Tables) HTML 36K
46: R33 Note Payable (Tables) HTML 36K
47: R34 Redeemable Noncontrolling Interest (Tables) HTML 51K
48: R35 Stockholders' Equity (Tables) HTML 38K
49: R36 Net Loss Per Share (Tables) HTML 59K
50: R37 Stock-Based Compensation (Tables) HTML 77K
51: R38 Fair Value Measurements (Tables) HTML 70K
52: R39 Basis of Presentation (Details) HTML 41K
53: R40 License and Distribution Agreements (Details) HTML 68K
54: R41 Summary of Significant Accounting Policies HTML 28K
(Details)
55: R42 Investment in Equity Securities, at fair value and HTML 27K
long-term investments - Summary of Investment
(Details)
56: R43 Investment in Equity Securities, at fair value and HTML 38K
long-term investments - Summary of Long-term
investment (Details)
57: R44 Investment in Equity Securities, at fair value and HTML 67K
long-term investments - Additional Information
(Details)
58: R45 Investment in Equity Securities, at fair value and HTML 28K
long-term investments (Details)
59: R46 Inventories (Details) HTML 33K
60: R47 Leases - Impact of Topic 842 (Details) HTML 29K
61: R48 Leases - Supplemental Cash Flow (Details) HTML 28K
62: R49 Leases - Future Undiscounted Cash Flows (Details) HTML 42K
63: R50 Leases - Additional Information (Details) HTML 53K
64: R51 Intangible Assets - Net Definite-lived Intangible HTML 35K
Assets (Details)
65: R52 Intangible Assets - Expected Future Amortization HTML 37K
Expense (Details)
66: R53 Intangible Assets - Additional Information HTML 43K
(Details)
67: R54 Assets Held for Sale - Components of assets HTML 36K
held-for-sale (Details)
68: R55 Assets Held for Sale - Additional Information HTML 46K
(Details)
69: R56 Grants (Details) HTML 36K
70: R57 Note Payable (Details) HTML 42K
71: R58 Note Payable - Additional Information (Details) HTML 29K
72: R59 Redeemable Noncontrolling Interest - Changes HTML 34K
(Details)
73: R60 Redeemable Noncontrolling Interest - Additional HTML 41K
Information (Details)
74: R61 Stockholders' Equity (Details) HTML 48K
75: R62 Stockholders' Equity - Additional Information HTML 42K
(Details)
76: R63 Net Loss Per Share (Details) HTML 27K
77: R64 Net Loss Per Share - Basic and diluted net loss HTML 42K
per share computation (Details)
78: R65 Stock-Based Compensation - Compensation Expense HTML 31K
(Details)
79: R66 Stock-Based Compensation - Weighted-Average HTML 41K
Assumptions (Details)
80: R67 Stock-Based Compensation - Options Outstanding HTML 57K
(Details)
81: R68 Stock-Based Compensation - Additional Information HTML 41K
(Details)
82: R69 Income Taxes (Details) HTML 25K
83: R70 Fair Value Measurements (Details) HTML 48K
84: R71 Fair Value Measurements - Additional Information HTML 39K
(Details)
85: R72 Related Party Transactions (Details) HTML 49K
86: R73 Commitments (Details) HTML 29K
87: R74 Subsequent Event (Details) HTML 47K
89: XML IDEA XML File -- Filing Summary XML 163K
13: XML XBRL Instance -- casi-20200930x10q_htm XML 1.63M
88: EXCEL IDEA Workbook of Financial Reports XLSX 97K
9: EX-101.CAL XBRL Calculations -- casi-20200930_cal XML 162K
10: EX-101.DEF XBRL Definitions -- casi-20200930_def XML 430K
11: EX-101.LAB XBRL Labels -- casi-20200930_lab XML 1.08M
12: EX-101.PRE XBRL Presentations -- casi-20200930_pre XML 889K
8: EX-101.SCH XBRL Schema -- casi-20200930 XSD 199K
90: JSON XBRL Instance as JSON Data -- MetaLinks 360± 535K
91: ZIP XBRL Zipped Folder -- 0001104659-20-122981-xbrl Zip 255K
‘EXCEL’ — IDEA Workbook of Financial Reports
This is an IDEA Workbook.
10 Subsequent Filings that Reference this Filing
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent
3/28/24 CASI Pharmaceuticals, Inc. 20-F 12/31/23 142:21M Toppan Merrill Bridge/FA
4/26/23 CASI Pharmaceuticals, Inc. 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA
4/26/23 CASI Pharmaceuticals, Inc. (DE) 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA
3/28/22 CASI Pharmaceuticals, Inc. (DE) 10-K 12/31/21 104:11M Toppan Merrill Bridge/FA
10/29/21 CASI Pharmaceuticals, Inc. (DE) 424B5 1:316K Toppan Merrill/FA
3/30/21 CASI Pharmaceuticals, Inc. (DE) 10-K 12/31/20 109:13M Toppan Merrill Bridge/FA
3/25/21 CASI Pharmaceuticals, Inc. (DE) 424B5 1:389K Toppan Merrill/FA
3/23/21 CASI Pharmaceuticals, Inc. (DE) 424B5 1:391K Toppan Merrill/FA
2/10/21 CASI Pharmaceuticals, Inc. (DE) 10-Q/A 9/30/20 13:304K Toppan Merrill/FA
11/20/20 CASI Pharmaceuticals, Inc. (DE) S-3 3:264K Toppan Merrill/FA
|
1 Previous Filing that this Filing References
↑Top
Filing Submission 0001104659-20-122981 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help —
Sat., May 11, 6:03:53.2am ET 
